A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy

Published:2019-10-14 Issue:1 Volume:20 Page:57-68
ISSN:1470-269X
Container-title:The Pharmacogenomics Journal
language:en
Short-container-title:Pharmacogenomics J

Author:

Lin Chen-Chun,Hsu Chao-Wei,Chen Yi-Cheng,Chang Ming-Ling,Liang Kung-Hao,Lai Ming-Wei,Lin Chih-Lang,Chien Rong-Nan,Lin Kwang-Huei,Yeh Chau-Ting

Funder

Chang Gung Memorial Hospital, Linkou

Ministry of Health and Welfare

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine

Link

http://www.nature.com/articles/s41397-019-0106-0.pdf

Reference26 articles.

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.

2. Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol. 2014;184:574–83.

3. Yeh CT, Chen HC, Sung CM, Hsu CL, Lin CC, Pan KT, et al. Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. BMC Cancer. 2011;11:117.

4. Llovet JM, Real MI, Montaña X, Planas R, Col S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.

5. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An SNP Marker Predicts Colorectal Cancer Outcomes with 5-Fluorouracil-Based Adjuvant Chemotherapy Post-Resection;International Journal of Molecular Sciences;2024-06-17

2. Predicting the prognosis of hepatic arterial infusion chemotherapy in hepatocellular carcinoma;World Journal of Gastrointestinal Oncology;2024-06-15

3. Potentially functional genetic variants in ferroptosis‐related CREB3 and GALNT14 genes predict survival of hepatitis B virus‐related hepatocellular carcinoma;Cancer Medicine;2023-12-27

4. Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib;Cancer Biomarkers;2023-04-06

5. A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma;International Journal of Molecular Sciences;2023-01-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3